Key clinical issues in renal cancer: A challenge for proteomics

World Journal of Urology

Volumn 25, Issue 6, 2007, Pages 537-556

  Banks, Rosamonde E ^a   Craven, Rachel A ^a   Harnden, Patricia ^a   Madaan, Sanjeev ^a   Joyce, Adrian ^a   Selby, Peter J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Proteomics; Renal cancer; Therapy; Tumour marker

Indexed keywords

TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; METHODOLOGY; ONCOLOGY; PROGNOSIS; PROTEOMICS; REVIEW; TUMOR CELL LINE; UROLOGY;

ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASM PROTEINS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; UROLOGY;

EID: 36248985698     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0199-y     Document Type: Review

References (111)

1. Drucker BJ (2005) Renal cell carcinoma: Current status and future prospects. Cancer Treat Rev 31:536-545
2. Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166:1611-1623
3. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Maher ER, et al (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66:2000-2011
4. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Voller MC, De WK, Mulders PF, et al (2007) Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 30:116-122
5. Silver DA, Morash C, Brenner P, Campbell S, Russo P (1997) Pathologic findings at the time of nephrectomy for renal mass. Ann Surg Oncol 4:570-574
6. Licht MR (1995) Renal adenoma and oncocytoma. Semin Urol Oncol 13:262-266
7. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117:272-275
8. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659
9. Shingleton WB, Sewell PE Jr (2001) Percutaneous renal tumor cryoablation with magnetic resonance imaging guidance. J Urol 165:773-776
10. McDougal WS, Gervais DA, McGovern FJ, Mueller PR (2005) Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent. J Urol 174:61-63
11. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR (2005) Radiofrequency ablation of renal cell carcinoma: Part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 185:64-71
12. Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR (2005) Radiofrequency ablation of renal cell carcinoma: Part 2, Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 185:72-80
13. Wu F, Wang ZB, Chen WZ, Bai J, Zhu H, Qiao TY (2003) Preliminary experience using high intensity focused ultrasound for the treatment of patients with advanced stage renal malignancy. J Urol 170:2237-2240
14. Illing RO, Kennedy JE, Wu F, ter Haar GR, Protheroe AS, Friend PJ, et al (2005) The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population. Br J Cancer 93:890-895
15. Swanson DA, Wallace S, Johnson DE (1980) The role of embolization and nephrectomy in the treatment of metastatic renal carcinoma. Urol Clin North Am 7:719-730
16. Gallucci M, Guaglinone S, Carpanese L, Papalia R, Simone G, Forestiere E, et al (2007) Superselective embolization as first step of laparoscopic partial nephrectomy. Urology 69:642-645
17. MRC Renal Cancer Working Party 1998 (1999) Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical research council renal cancer collaborators. Lancet 353:14-17
18. Atzpodien J, Kirchner H, Rebmann U, Soder M, Gertenbach U, Siebels M, et al (2006) Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 95:463-469
19. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
20. Bankhead C (2006) Three new drugs available to fight kidney cancer. J Natl Cancer Inst 98:1181-1182
21. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512
22. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
23. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
24. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19:1649-1657
25. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, et al (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38:489-494
26. Bell ET (1950) Renal diseases. Lea & Febiger, Philadelphia
27. Eschwege P, Saussine C, Steichen G, Delepaul B, Drelon L, Jacqmin D (1996) Radical nephrectomy for renal cell carcinoma 30 mm. or less: long-term follow results. J Urol 155:1196-1199
28. Mastofi FK, Davis CJ, Sobin LH (1998) Histological typing of kidney tumours, 2nd edn. Springer, Berlin, Heidelberg
29. Kovacs G, Fuzesi L, Emanual A, Kung HF (1991) Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 3:249-255
30. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al (1997) The Heidelberg classification of renal cell tumours. J Pathol 183:131-133
31. Abrahams NA, MacLennan GT, Khoury JD, Ormsby AH, Tamboli P, Doglioni C, et al (2004) Chromophobe renal cell carcinoma: A comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology 45:593-602
32. Kuroda N, Toi M, Yamamoto M, Miyazaki E, Hayashi Y, Hiroi M, et al (2004) Immunohistochemical identification of intracytoplasmic lumens by cytokeratin typing may differentiate renal oncocytomas from chromophobe renal cell carcinomas. Histol Histopathol 19:23-28
33. Wang HY, Mills SE (2005) KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am J Surg Pathol 29:640-646
34. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M (2005) Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: A tissue microarray study. Mod Pathol 18:535-540
35. Rampino T, Gregorini M, Soccio G, Maggio M, Rosso R, Malvezzi P, et al (2003) The Ron proto-oncogene product is a phenotypic marker of renal oncocytoma. Am J Surg Pathol 27:779-785
36. Patton KT, Tretiakova MS, Yao JL, Papavero V, Huo L, Adley BP, et al (2004) Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. Am J Surg Pathol 28:1045-1050
37. Mazal PR, Exner M, Haitel A, Krieger S, Thomson RB, Aronson PS, et al (2005) Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol 36:22-28
38. Adley BP, Gupta A, Lin F, Luan C, Teh BT, Yang XJ (2006) Expression of kidney-specific cadherin in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 126:79-85
39. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD (2005) Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol 18:933-940
40. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20:4559-4566
41. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, et al (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173:48-51
42. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer 97:1663-1671
43. Lohse CM, Cheville JC (2005) A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 25:433-464
44. UICC (2002) TNM classification of malignant tumors, 6th edn. Wiley, New York
45. Soilleux EJ, Roberts IS (2006) Assessment of the Cardiff nephrectomy cut-up protocol with total blocking of the renal sinus: Effect on tumour staging and practical issues. J Clin Pathol 59:1209-1211
46. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663
47. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H (2002) Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 59:532-537
48. Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, de Peralta VM, et al (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 26:281-291
49. Ficarra V, Righetti R, Pilloni S, D'Amico A, Maffei N, Novella G, et al (2002) Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 41:190-198
50. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV (2005) Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: A retrospective nation-wide study of 629 patients. Eur Urol 48:593-600
51. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al (2005) Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol 23:2763-2771
52. Al-Aynati M, Chen V, Salama S, Shuhaibar H, Treleaven D, Vincic L (2003) Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med 127:593-596
53. Craven RA, Banks RE (2001) Laser capture microdissection and proteomics: possibilities and limitation. Proteomics 1:1200-1204
54. Anderson NL, Anderson NG (2002) The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1:845-867
55. Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin EF III, Liotta LA, et al (2004) An investigation into the human serum "interactome". Electrophoresis 25:1289-1298
56. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, et al (2004) Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: A novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 3:327-344
57. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, et al (2005) Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51:1637-1649
58. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198-207
59. Palagi PM, Hernandez P, Walther D, Appel RD (2006) Proteome informatics I: Bioinformatics tools for processing experimental data. Proteomics 6:5435-5444
60. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, et al (2003) A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3:36-44
61. Gorg A, Weiss W, Dunn MJ (2004) Current two-dimensional electrophoresis technology for proteomics. Proteomics 4:3665-3685
62. Soldi M, Sarto C, Valsecchi C, Magni F, Proserpio V, Ticozzi D, et al (2005) Proteome profile of human urine with two-dimensional liquid phase fractionation. Proteomics 5:2641-2647
63. Sheng S, Chen D, Van Eyk JE (2006) Multidimensional liquid chromatography separation of intact proteins by chromatographic focusing and reversed phase of the human serum proteome: Optimization and protein database. Mol Cell Proteomics 5:26-34
64. Jin Y, Manabe T (2005) Direct targeting of human plasma for matrix-assisted laser desorption/ionization and analysis of plasma proteins by time of flight-mass spectrometry. Electrophoresis 26:2823-2834
65. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, et al (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. The Lancet 362:433-439
66. Tang N, Tornatore P, Weinberger SR (2004) Current developments in SELDI affinity technology. Mass Spectrom Rev 23:34-44
67. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, et al (2005) Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 51:102-112
68. Rai AJ, Stemmer PM, Zhang Z, Adam BL, Morgan WT, Caffrey RE, et al (2005) Analysis of human proteome organization plasma proteome project (HUPO PPP) reference specimens using surface enhanced laser desorption/ ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 5:3467-3474
69. Chaurand P, Norris JL, Cornett DS, Mobley JA, Caprioli RM (2006) New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J Proteome Res 5:2889-2900
70. Wolters DA, Washburn MP, Yates JR III (2001) An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 73:5683-5690
71. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al (2002) Stable isotope labelling by amino acids in cell culture, SILAC, as a simplae and accurate apporach to expression proteomics. Mol Cell Proteomics 1:376-386
72. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al (2004) Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3:1154-1169
73. Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, et al (1997) Renal cell carcinoma and normal kidney protein expression. Electrophoresis 18:599-604
74. Sarto C, Frutiger S, Cappellano F, Sanchez JC, Doro G, Catanzaro F, et al (1999) Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma. Electrophoresis 20:3458-3466
75. Balabanov S, Zimmermann U, Protzel C, Scharf C, Klebingat KJ, Walther R (2001) Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem 268:5977-5980
76. Dallmann K, Junker H, Balabanov S, Zimmermann U, Giebel J, Walther R (2004) Human agmatinase is diminished in the clear cell type of renal cell carcinoma. Int J Cancer 108:342-347
77. Zimmermann U, Balabanov S, Giebel J, Teller S, Junker H, Schmoll D, et al (2004) Increased expression and altered location of annexin IV in renal clear cell carcinoma: A possible role in tumour dissemination. Cancer Lett 209:111-118
78. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, et al (2003) Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3:1620-1632
79. Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, et al (2005) Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci 20:450-455
80. Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, et al (2005) Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics 5:2631-2640
81. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, et al (2006) Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 5:64
82. Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A, et al (2006) A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 25:7138-7147
83. Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, et al (2007) Ubiquitin COOH-terminal hydrolase 1: A biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res 13:27-37
84. Poznanovic S, Wozny W, Schwall GP, Sastri C, Hunzinger C, Stegmann W, et al (2005) Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectric focusing in serial immobilized pH gradient gels. J Proteome Res 4:2117-2125
85. Zhuang Z, Huang S, Kowalak JA, Shi Y, Lei J, Furuta M, et al (2006) From tissue phenotype to proteotype: Sensitive protein identification in microdissected tumor tissue. Int J Oncol 28:103-110
86. Bloom GC, Eschrich S, Zhou JX, Coppola D, Yeatman TJ (2007) Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer 120:769-775
87. Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, Rybak JN, et al (2006) A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 5:2083-2091
88. von Eggeling F, Junker K, Fiedle W, Wollscheid V, Durst M, Claussen U, et al (2001) Mass spectrometry meets chip technology: A new proteomic tool in cancer research? Electrophoresis 22:2898-2902
89. Junker K, Gneist J, Melle C, Driesch D, Schubert J, Claussen U, et al (2005) Identification of protein pattern in kidney cancer using ProteinChip arrays and bioinformatics. Int J Mol Med 15:285-290
90. Fetsch PA, Simone NL, Bryant-Greenwood PK, Marincola FM, Filie AC, Petricoin EF, et al (2002) Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: Potential for diagnostic applications. Am J Clin Pathol 118:870-876
91. Craven RA, Stanley AJ, Hanrahan S, Dods J, Unwin R, Totty N, et al (2006) Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 6:2853-2864
92. Perego RA, Bianchi C, Corizzato M, Eroini B, Torsello B, Valsecchi C, et al (2005) Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues. J Proteome Res 4:1503-1510
93. Shi T, Dong F, Liou LS, Duan ZH, Novick AC, DiDonato JA (2004) Differential protein profiling in renal-cell carcinoma. Mol Carcinog 40:47-61
94. Craven RA, Hanrahan S, Totty N, Harnden P, Stanley AJ, Maher ER, et al (2006) Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 6:3880-3893
95. Nakamura E, Abreu-e-Lima, Awakura Y, Inoue T, Kamoto T, Ogawa O, et al (2006) Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 168:574-584
96. Nakamura K, Yoshikawa K, Yamada Y, Saga S, Aoki S, Taki T, et al (2006) Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology. Int J Oncol 28:965-970
97. Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, et al (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 95:298-306
98. Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, et al (2004) Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4:1159-1174
99. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, et al (2003) Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionisation (SELDI) and neural network analysis: Identification of key issues affecting potential clinical utility. Cancer Res 63:6971-6983
100. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW (2003) Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 3:2310-2316
101. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, et al (2004) Serum protein profiling by SELDI mass spectrometry: Detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84:845-856
102. Rossi L, Martin BM, Hortin GL, White RL, Foster M, Moharram R, et al (2006) Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 6:709-720
103. Panelli MC, White R, Foster M, Martin B, Wang E, Smith K, et al (2004) Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2:17
104. Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K, Adolf GR (2001) Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1:890-898
105. Lichtenfels R, Kellner R, Bukur J, Beck J, Brenner W, Ackermann A, et al (2002) Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2:561-570
106. Kellner R, Lichtenfels R, Atkins D, Bukur J, Ackermann A, Beck J, et al (2002) Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2:1743-1751
107. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, et al (2003) Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 1646:21-31
108. Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, et al (2003) Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3:45-55
109. Kruger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J (2005) Lessons to be learned from primary renal cell carcinomas: Novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 54:826-836
110. Weinzierl AO, Lemmel C, Schoor O, Muller M, Kruger T, Wernet D, et al (2007) Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics 6:102-113
111. Flad T, Mueller L, Dihazi H, Grigorova V, Bogumil R, Beck A (2006) T cell epitope definition by differential mass spectrometry: identification of a novel, immunogenic HLA-B8 ligand directly from renal cancer tissue. Proteomics 6:364-374